PT  - JOURNAL ARTICLE
AU  - N Mavaddat
AU  - L Ficorella
AU  - T Carver
AU  - A Lee
AU  - AP Cunningham
AU  - M Lush
AU  - J Dennis
AU  - M Tischkowitz
AU  - K Downes
AU  - H Donglei
AU  - E Hahnen
AU  - R Schmutzler
AU  - T Stockley
AU  - G Downs
AU  - T Zhang
AU  - AM Chiarelli
AU  - S Bojesen
AU  - L Cong
AU  - WK Chung
AU  - M Pardo
AU  - L Feliubadaló
AU  - J Balmana
AU  - J Simard
AU  - AC Antoniou
AU  - DF Easton
TI  - Incorporating alternative Polygenic Risk Scores into the BOADICEA breast cancer risk prediction model
AID  - 10.1101/2022.07.08.22276452
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.07.08.22276452
4099  - http://medrxiv.org/content/early/2022/07/09/2022.07.08.22276452.short
4100  - http://medrxiv.org/content/early/2022/07/09/2022.07.08.22276452.full
AB  - Background The multifactorial risk prediction model BOADICEA enables identification of women at higher or lower risk of developing breast cancer. BOADICEA models genetic susceptibility in terms of the effects of rare variants in breast cancer susceptibility genes and a polygenic component, decomposed into an unmeasured and a measured component - the polygenic risk score (PRS). The current version was developed using a 313 SNP PRS. Here, we evaluated approaches to incorporating this PRS and alternative PRS in BOADICEA.Methods The mean, standard deviation (SD), and proportion of the overall polygenic component explained by the PRS (α2) need to be estimated. α was estimated using logistic regression, where the age-specific log-relative risk is constrained to be a function of the age-dependent polygenic relative risk in BOADICEA; and using a retrospective likelihood (RL) approach that models, in addition, the unmeasured polygenic component.Results Parameters were computed for 11 PRS, including 6 variations of the 313 SNP PRS used in clinical trials and implementation studies. The logistic regression approach underestimates α, as compared with the RL estimates. The RL α estimates were very close to those obtained by assuming proportionality to the odds ratio per 1 SD, with the constant of proportionality estimated using the 313 SNP PRS. Small variations in the SNPs included in the PRS can lead to large differences in the mean.Conclusions BOADICEA can be readily adapted to different PRS in a manner that maintains consistency of the model.Impact The methods described enable comprehensive breast cancer risk assessment.Competing Interest StatementCompeting interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare that: The BOADICEA model has been licensed to Cambridge Enterprise for commercialization, with the authors D.F.E., A.C.A., A.P.C., A.L. and T.C. listed as its inventors. A.P. has received royalties as a result of this. A.L. is an employee of Illumina Inc. and owns shares in Illumina Inc. A.A. T.C., J. D. and N.M. are funded by CanRisk CR-UK programme (PPRPGM-Nov20\100002) paid to the institution. N.M. is also funded through the PERSPECTIVE program. S.J. leads the PERSPECTIVE I&I project, which is funded by the Government of Canada through Genome Canada (#13529) and the Canadian Institutes of Health Research (#155865), the Ministère de l’Économie et de l’Innovation du Québec through Genome Québec, the Quebec Breast Cancer Foundation, the CHU de Quebec Foundation and the Ontario Research Fund (Payments made to institution Université Laval). SJ leads the PERSPECTIVE project supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (grant GPH-129344) and, the Ministère de l’Économie, Science et Innovation du Québec through Genome Québec and the PSRSIIRI-701 grant, and the Quebec Breast Cancer Foundation (Payments made to institution Université Laval). M.T. is funded by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) and Cancer Research UK C22770/A31523 (International Alliance for Cancer Early Detection programme). W.C. is funded by NIH grant U01 HG008680 (eMERGE grant). W.C. also received Consulting fees from and is on Scientific advisory board of Regeneron Genetics Center. W.C. is also on the Board of Directors of Prime Medicine. S.B. is funded by Region H and Boserup Foundation. These funders did not have any influence on the sample collection, lab work, data analyses or their interpretation. L Feliubadaló declares Payment or honoraria for lecture - Lecture on analysis of sequencing data from ovarian cancer presented to Astra-Zeneca. No other conflict of interest is reported.Funding StatementThis work has been supported by grants from Cancer Research UK (PPRPGM-Nov20\100002); the European Union’s Horizon 2020 research and innovation programme under grant agreement numbers 633784 (B-CAST) and 634935 (BRIDGES); the PERSPECTIVE I&I project which is funded by the Government of Canada through Genome Canada (#13529) and the Canadian Institutes of Health Research (#155865), the Ministère de l’Économie et de l’Innovation du Québec through Genome Québec, the Quebec Breast Cancer Foundation, the CHU de Quebec Foundation and the Ontario Research Fund; and by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). BCAC is funded by the European Union’s Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), and the PERSPECTIVE I&I project, funded by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the Ministère de l’Économie et de l’Innovation du Québec through Genome Québec, the Quebec Breast Cancer Foundation. The EU Horizon 2020 Research and Innovation Programme funding source had no role in study design, data collection, data analysis, data interpretation or writing of the report. Additional funding for BCAC is provided via the Confluence project which is funded with intramural funds from the National Cancer Institute Intramural Research Program, National Institutes of Health. Genotyping of the OncoArray was funded by the NIH Grant U19 CA148065, and Cancer Research UK Grant C1287/A16563 and the PERSPECTIVE project supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (grant GPH-129344) and, the Ministère de l’Économie, Science et Innovation du Québec through Genome Québec and the PSRSIIRI-701 grant, and the Quebec Breast Cancer Foundation. MT was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) and Cancer Research UK C22770/A31523 (International Alliance for Cancer Early Detection programme). The PRISMA study was supported by the Carlos III National Health Institute and Ministerio de Educación y Ciencia grant (PI19/01195); and CERCA Programa/Generalitat de Catalunya for institutional support (J. Balmaña). W. Chung was funded by NIH grant U01 HG008680 (eMERGE grant)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Declaration - All studies were approved by the relevant local ethical review boards and used appropriate consent procedures. SEARCH was approved by the NRES Committee East of England - Cambridge South. Study(Acronym)CountryApproval Committee(s) Australian Breast Cancer Tissue Bank(ABCTB)Australia-Sydney Local Health District (RPA Zone) Research Ethics and Governance Office; Agricultural Health Study(AHS)USA-National Institute of Health (NIH) Population Sciences IRB; Bavarian Breast Cancer Cases and Controls(BBCC)Germany-Friedrich-Alexander-Universitat Erlangen-Nurnberg Medizinische Fakultat Ethik-Commission; Breast Cancer Environment and Employment Study(BCEES)Australia-The University of Western Australia Human Ethics Research Committee; Breast Cancer In Northern Israel Study (BCINIS)Israel-Carmel Medical Center; Breast Oncology Galicia Network(BREOGAN)Spain-Comité Autonómico de Ética de la Investigación de Galicia; Canadian Breast Cancer Study(CBCS)Canada-University of British Columbia - BC Cancer Research -Ethics Board; Queen’s University Health Sciences and Affiliated Teaching Hospitals Research Human Ethics Board (HSREB); Crete Cancer Genetics Program(CCGP)Greece-Epistimoniko Symvoulio (Scientific Council of the University General hospital of Heraklion); Copenhagen General Population Study(CGPS)Denmark-Kobenhavns Amt den Videnskabsetiske Komite (Scientific ethical committee, Copenhagen County); Cancer Prevention Study-II Nutrition Cohort(CPSII)USA-Emory University Institutional Review Board; California Teachers Study(CTS)USA-UC Irvine: Office of Research Institutional Review Board; European Prospective Investigation Into Cancer and Nutrition(EPIC)Various within EU-Institutional Review Board of the International --Agency for Research on Cancer, Lyon, France; Ethics -Commission of the Faculty of Medicine of the University of Heidelberg; Family History Risk Study(FHRISK)UK-NRES Committee North West - Greater Manchester Central; Gene Environment Interaction and Breast Cancer in Germany(GENICA)Germany-Ethikkommission Rheinische Friedrich-Wilhels-Universitüt Bonn; Hannover Breast Cancer Study(HABCS)Germany-Medizinische Hochschule Hannover Ethik-Kommission; Karolinska Mammography Project for Risk Prediction of Breast Cancer - Cohort Study(KARMA)Sweden-Regionala Etikprovningsnamnden i Stockholm (Regional Ethical Review Board in Stockholm); Leuven Multidisciplinary Breast Centre(LMBC)Belgium-Commissie Medische Ethiek van de Universitaire -Ziekenhuizen Kuleuven; Mayo Clinic Breast Cancer Study(MCBCS)USA-Mayo Clinic IRB; Melbourne Collaborative Cohort Study(MCCS)Australia-The Cancer Council Victoria Human Research Ethics Committee; Melanoma Inquiry of Southern Sweden(MISS)Sweden-Regional Ethical Board in South Sweden; Mayo Mammography Health Study(MMHS)USA-Mayo Clinic IRB; Nashville Breast Health Study(NBHS)USA-Vanderbilt University Medical Center IRB; Nurses Health Study(NHS)USA-Partners Human Research, Partners Healthcare System (PHS) IRB; Nurses Health Study 2(NHS2)USA-Partners Human Research, Partners Healthcare System (PHS) IRB; Leiden University Medical Centre Breast Cancer Study(ORIGO)Netherlands-Medical Ethical Committee and Board of Directors of the Leiden University Medical Center (LUMC); NCI Polish Breast Cancer Study(PBCS)Poland-National Cancer Institute Special Studies Institutional Review Board (NCI-SSIRB); The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial(PLCO)USA-National Cancer Institute Special Studies Institutional Review Board (NCI-SSIRB); Predicting the Risk Of Cancer At Screening Study(PROCAS)UK-NRES Committee North West - Greater Manchester Central; Study of Epidemiology and Risk factors in Cancer Heredity(SEARCH)UK-Multi Centre Research Ethics Committee (MREC); The Sister Study(SISTER)USA-Institutional Review Board of the National Institute of Environmental Health Sciences; NIH and the Copernicus Group Independent Review Board; Swedish Mammography Cohort(SMC)Sweden-Regionala Etikprovningsnamnden i Stockholm (Regional Ethical Review Board in Stockholm); UCI Breast Cancer Study(UCIBCS)USA-UC Irvine: Office of Research Institutional Review Board; UK Breakthrough Generations Study(UKBGS)UK- London- South East Research Ethics Committee; Women’s Health Initiative(WHI)USA-Fred Hutchinson Cancer Research CenterI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available on request.